VitaKine platelet cell therapy from bioparadox improves cardiac function after heart attack

BioParadox founder Dr. Allan Mishra presents preclinical study data at the 2nd Annual Translational Regenerative Medicine Forum

2011-04-08

(Press-News.org) Menlo Park, Calif.—April 7, 2011—BioParadox, Inc., a regenerative medicine company pioneering point-of-care biologic treatments for cardiovascular disease, today announced data supporting the use of VitaKine® Platelet Cell Therapy (PCT) as a promising treatment for heart attack patients. The results of a preclinical cardiac study were presented at the 2nd Annual Translational Regenerative Medicine Forum in Washington, D.C.

Platelet-Rich Plasma (PRP), a component of whole blood, has been shown to effectively treat sports-related injuries such as chronic tennis elbow in randomized controlled trials. With two recent preclinical studies, BioParadox has demonstrated the effectiveness of Platelet Cell Therapy, a proprietary subset of PRP, to safely and effectively enhance the function of cardiac tissue damaged by myocardial infarction (heart attack). Left untreated, the heart is unable to regain its muscle pumping action, also known as ejection fraction. Progressive lack of function can lead to congestive heart failure or even death.

Working with colleagues at Stanford University Medical Center, Dr. Allan Mishra and Dr. Todd Brinton studied the effects of PCT – proprietary formulations of concentrated platelets and white blood cells – on cardiac function after inducing a heart attack in a pivotal swine model. VitaKine PCT was found to significantly enhance the amount of blood pumped out of the ventricles (ejection fraction) by 23% compared to controls (p < 0.05). Standard PRP did not improve pumping action. VitaKine PCT contains white blood cells in specific ratios and concentrations, in addition to platelets.

"From a decade of research in sports medicine with Platelet-Rich Plasma, we have seen its effectiveness as a biologic therapeutic for improving tissue healing," said Dr. Allan Mishra, founder of BioParadox. "With this new study, we are translating the benefit of PRP from sports medicine to cardiovascular care with more precise formulations such as VitaKine PCT. BioParadox's preclinical studies show tremendous potential for treating patients who have suffered from a heart attack, congestive heart failure or peripheral vascular disease, among other conditions."

The BioParadox VitaKine PCT research study was conducted at Stanford University under the direction of Principal Investigator Dr. Alan Yeung, professor of medicine and chief, division of cardiovascular medicine. "The results from our preclinical animal model studies are promising and support the initiation of human trials." said Dr. Yeung. "The study also represents a novel approach to a challenging clinical problem without the risk of rejection or the costs of extensive stem cell processing."

"Coronary heart disease is the leading cause of death in industrialized nations, with nearly half a million heart attacks each year, and near-epidemic numbers of patient with heart failure," said Dr. Warren Sherman, director of stem cell research and regenerative medicine at the Center for Intervention Vascular Therapies at NewYork-Presbyterian Hospital/Columbia University Medical Center. "BioParadox's Platelet Cell Therapy (PCT) shows significant potential to create a paradigm shift in biologic therapy for damaged myocardial tissue and improve cardiovascular care."

### Taking place April 6-8, 2011 at the Ronald Reagan Building and International Trade Center in Washington, D.C., the Translational Regenerative Medicine Forum is an international event convening members of the academic, clinical, pharmaceutical, government and venture capitalist community to collaborate and advance the science of regenerative medicine.

Dr. Mishra and Dr. Brinton are members of the BioParadox Board of Directors. Dr. Sherman is a member of the BioParadox Scientific Advisory Board. Dr. Yeung was the study's principal investigator and has no conflict of interest.

About BioParadox BioParadox is innovating the use of Platelet Cell Therapy (PCT) for the treatment of cardiovascular disease. The company's first products, VitaKine®and RevaTen® are proprietary formulations that have been shown to enhance cardiovascular function. They are produced exclusively by BioParadox.

For more information, please visit: BioParadox.com or e-mail: info@bioparadox.com.

About the Regenerative Medicine Foundation The Regenerative Medicine Foundation (www.regenerativemedicinefoundation.org), launched in 2005, is an internationally-focused, not-for-profit organization created to enable the advancement of new treatments and therapies based on regenerative medicine, and ultimately, to realize the goals of personalized medicine. Through educational programs, translational conferences and public policy initiatives, the Foundation advocates for increased medical research, promotes the training and education of scientists, and facilitates the translation of therapies to patients.

Media Contact:
Brianne Donahue / Kristin Villiotte
Schwartz Communications
(415) 512-0770 / (781) 684-0770
bioparadox@schwartzcomm.com

ELSE PRESS RELEASES FROM THIS DATE:

Sand drift explained

2011-04-08

Researchers in countries such as Denmark, the Netherlands and Poland study sand drift, but most of them are focusing on sand dunes along the coastline, not on the plains further inland. "Sand dunes are dynamic. For all we know, they may have been formed last year. But sand plaines are much older and in periods more stable. Thin organic layers present in sands are interesting, when trying to understand sand drift in pre-historic times," says botanist Lisbeth Prøsch-Danielsen at the University of Stavanger's Museum of Archaeology. Together with her colleague, geologist ...

VA makes major gains in quality, but racial disparity persists

2011-04-08

PROVIDENCE, R.I. [Brown University] — As recently as the 1990s, the Veterans Affairs health care system had a subpar reputation for quality, but two new studies of standard quality metrics, both led by Amal Trivedi, assistant professor of community health at Brown University and a physician at the Providence VA Medical Center, show that the system that cares for more than 5 million patients has improved markedly in the last decade. In one study, published online March 18 in the journal Medical Care, Trivedi found that the VA's care for seniors is consistently better than ...

Deep-space travel could create heart woes for astronauts

2011-04-08

Astronauts anticipate more trips to the moon and manned missions to Mars. But exposure to cosmic radiation outside the Earth's magnetic field could be detrimental to their arteries, according to a study by University of Alabama at Birmingham researchers published April 6, 2011, online in the journal Radiation Research. Using an animal model, researchers assessed the affect of iron ion radiation commonly found in outer space to see if exposures promoted the development of atherosclerosis, as terrestrial sources of radiation are known to do. They observed that cosmic radiation ...

Michigan's collaborative quality improvement program cuts costs, improves patient care

2011-04-08

Ann Arbor, Mich. -- In a paper published today in the professional health care journal, Health Affairs, Blue Cross Blue Shield of Michigan and the University of Michigan Health System report that their model for collaborative health care quality improvement has measurably improved safety and quality in several clinical areas, and has saved millions in health care costs. Collaborative quality initiatives, the term given to the payer-hospital initiatives aimed at improving safety and quality of specific surgical procedures and clinical practices, have been shown to outpace ...

Scientists have new measure for species threat

2011-04-08

A new index has been developed to help conservationists better understand how close species are to extinction. The index, developed by a team of Australian researchers from the University of Adelaide and James Cook University, is called SAFE (Species Ability to Forestall Extinction). The SAFE index builds on previous studies into the minimum population sizes needed by species to survive in the wild. It measures how close species are to their minimum viable population size. "SAFE is a leap forward in how we measure relative threat risk among species," says co-author ...

Number of days of rain in Iberian Peninsula has increased since 1903

2011-04-08

A research team, led by the University of Extremadura, has for the first time analysed the frequency of rainfall over the whole of the Iberian Peninsula from 1903 to 2003. The results show that the number of rainy days increased over the 20th Century, except in the area of the Gulf of Cádiz and in western Portugal. However, rainfall has become less and less intense, except in these two regions. The study, which used daily precipitation data from 27 stations in Spain and Portugal, provides the first long-term evaluation of changes to rainfall over the Iberian Peninsula. ...

Climate change poses major risks for unprepared cities

2011-04-08

Cities worldwide are failing to take necessary steps to protect residents from the likely impacts of climate change, even though billions of urban dwellers are vulnerable to heat waves, sea level rise and other changes associated with warming temperatures. A new examination of urban policies by Patricia Romero Lankao at the National Center for Atmospheric Research (NCAR) in Boulder, Colo., in conjunction with an international research project on cities and climate change, warns that many of the world's fast-growing urban areas, especially in developing countries, will ...

Researchers present new findings on cancer and gene therapy

2011-04-08

WASHINGTON, April 7, 2011 – DNA's role as the master blueprint of the cell means that even small sequence changes can have catastrophic consequences. For this reason, much of our understanding of cancer development comes from studying how cells copy DNA and repair sequence errors -- and how these processes can go wrong. Next week, a thematic program at the American Society for Biochemistry and Molecular Biology's annual meeting at the Experimental Biology 2011 conference in Washington, D.C., will bring together researchers from across the country to discuss recent developments ...

Science at a glance: Symposia, research and special events at Experimental Biology 2011

2011-04-08

WASHINGTON (April 8, 2011) — The meeting Experimental Biology 2011 (EB 2011) begins April 9 and runs through April 13 at the Walter E. Washington Convention Center in Washington, D.C. This year's meeting is expected to attract some 13,000 scientists and exhibitors. The annual gathering is jointly sponsored by the American Association of Anatomists (AAA), American Physiological Society (APS), American Society for Biochemistry and Molecular Biology (ASBMB), American Society for Investigative Pathology (ASIP), American Society for Nutrition (ASN), and American Society for ...

Golden Riviera Casino Introduces ThunderStruck 2 as its Free Spins Feature

2011-04-08

Golden Riviera Online Casino announced today that it is adopting ThunderStruck 2 as its main Free Spins game for players who play online casino games. This announcement came in light of recent surveys, which indicated that ThunderStruck 2 is one of the most popular and sought after Microgaming casino games. New players at the casino can enjoy 50 Free Spins on the casino with their first deposit. Emily Alessi, Casino Manager at Golden Riviera Online Casino, said, "We are thrilled at the prospect of having one of the most prominent games at our casino as our Free Spins ...

VitaKine platelet cell therapy from bioparadox improves cardiac function after heart attack

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: